When Fertility Suppression on Testosterone Cypionate Becomes a Reason to Stop

By
Published Updated Last reviewed
Medication safety clinical consultation image for When Fertility Suppression on Testosterone Cypionate Becomes a Reason to Stop

When Fertility Suppression on Testosterone Cypionate Becomes a Reason to Stop

At a glance

  • Incidence of severe oligospermia or azoospermia on TRT: 40 to 90 percent within 3 months, depending on dose and assay sensitivity (Contraceptive efficacy of testosterone, WHO 1990)
  • Typical timeline to azoospermia: 60 to 90 days at standard 100 to 200 mg/week dosing
  • First-line management (if stopping is not yet desired): Add hCG 500 to 1500 IU subcutaneously 2 to 3 times weekly to maintain intratesticular testosterone
  • When to escalate: No sperm recovery after 6 months off testosterone, or confirmed azoospermia with an active conception window closing
  • When to discontinue: Active conception planning, <1 million sperm/mL with no response to adjunct hCG after 3 months, or patient priority shift toward paternity over TRT symptom relief

Why This Suppression Is Not Like Other TRT Side Effects

Most TRT side effects, such as erythrocytosis or acne, sit on a spectrum where dose reduction or a topical agent buys time. Fertility suppression does not work that way. The mechanism is direct and near-universal: exogenous testosterone signals the hypothalamus and pituitary to reduce gonadotropin-releasing hormone pulsatility, collapsing LH and FSH to undetectable levels. Without LH, Leydig cells stop producing intratesticular testosterone. Without FSH and intratesticular testosterone at concentrations 50 to 100 times higher than serum levels, Sertoli cells cannot support spermatogenesis. The result is azoospermia or severe oligospermia in the vast majority of users, typically within 60 to 90 days of starting a standard weekly injection regimen.

This is not a fringe finding. The WHO Task Force on Methods for the Regulation of Male Fertility demonstrated that weekly intramuscular testosterone enanthate (pharmacokinetically similar to cypionate) induced azoospermia in 71 percent of study participants within 6 months, with suppression to <3 million sperm/mL in over 98 percent. At doses commonly used in TRT (100 to 200 mg/week cypionate), suppression is consistent and rapid. Patients need to understand that this is not dose-dependent in the way they may hope: lower doses still suppress gonadotropins enough to halt spermatogenesis in most men.

The Clinical Thresholds That Define "Reason to Stop"

The decision to discontinue is not simply about a number on a semen analysis. It involves four intersecting criteria.

1. Conception Timeline

If a patient or their partner is actively trying to conceive within 12 to 18 months, that is the single clearest indication to stop testosterone cypionate now. Waiting for a "last cycle" or attempting to time injections around an ovulation window does not work because the suppression is systemic and persistent. A 2016 review in Fertility and Sterility confirmed that median time to return of any sperm after stopping exogenous testosterone is approximately 3 to 6 months, but full return to baseline (if it occurs) may take 12 to 24 months. A closing fertility window, particularly if a female partner is over 35, shifts the risk-benefit calculation sharply toward stopping.

2. Semen Analysis Values

Every patient on testosterone cypionate who has any future interest in biological paternity should have a baseline semen analysis before starting, and repeat testing at 3 months and 6 months of use. The laboratory thresholds that should prompt a serious discontinuation conversation are:

  • Total motile sperm count <1 million (severe oligospermia, functionally equivalent to azoospermia for natural conception)
  • Confirmed azoospermia on two separate samples at least 4 weeks apart
  • Progressive motility <10 percent with low total count, even if raw concentration appears borderline

Per WHO 2021 reference values, the lower reference limit for total motile sperm count is 9.7 million per ejaculate. Being more than a full order of magnitude below that threshold on TRT is not a minor deviation; it is a functional barrier to conception without assisted reproduction.

3. Failure to Respond to Adjunct hCG

For patients who want to preserve fertility while staying on TRT, co-administration of human chorionic gonadotropin (hCG) is a validated adjunct. hCG acts as an LH analog, directly stimulating Leydig cells to maintain intratesticular testosterone production even in the absence of pituitary LH. A standard protocol of 500 IU subcutaneously every other day has been shown to maintain intratesticular testosterone and preserve spermatogenesis in a subset of patients. Coviello et al. (2005) demonstrated that hCG co-administration at 250 IU every other day maintained intratesticular testosterone within normal ranges despite exogenous testosterone-induced LH suppression.

However, hCG alone is not sufficient for all patients. FSH is not replicated by hCG, and FSH has independent roles in Sertoli cell function and spermatid maturation. If a patient on testosterone cypionate plus hCG shows <1 million total motile sperm on two consecutive analyses at least 8 weeks apart, the combination is not working adequately for fertility preservation. At that point, a genuine choice must be made: stay on testosterone and pursue sperm banking or assisted reproduction, or discontinue and attempt recovery.

4. Duration of Exposure

Time on testosterone cypionate before stopping matters for two reasons. First, longer exposure may deepen hypothalamic-pituitary suppression, potentially prolonging recovery. Second, it affects how urgently a patient should be counseled. A Ramasamy et al. systematic review (2014) found that men who used exogenous androgens for more than 12 months had longer recovery times and a higher rate of incomplete recovery compared to shorter-term users. The data do not support a clean "safe duration," but clinical consensus suggests that crossing the 12-month mark without any fertility-preservation strategy in place materially increases the risk of prolonged or incomplete azoospermia even after stopping.

What to Switch To: The Post-TRT Protocol

Stopping testosterone cypionate is step one. What comes next determines how fast and how fully spermatogenesis recovers.

Step 1: Discontinue testosterone cypionate entirely. There is no validated "taper" strategy. The half-life of testosterone cypionate is 8 days, so serum testosterone declines to low-normal or hypogonadal levels within 3 to 4 weeks of the last injection. Endogenous LH and FSH should begin rising within 4 to 8 weeks.

Step 2: Start gonadotropin stimulation. For patients with confirmed hypogonadotropic suppression (low LH, low FSH, low serum testosterone 6 to 8 weeks after stopping), initiating hCG 1500 to 3000 IU three times weekly with or without recombinant FSH (follitropin alfa) accelerates testicular recovery. The Lipshultz et al. guidelines on male hypogonadism (2010) support this approach for exogenous androgen-induced azoospermia. hCG alone is often sufficient if pre-TRT spermatogenesis was normal. Adding recombinant FSH is appropriate when repeat semen analysis at 3 months post-hCG initiation shows no sperm despite rising LH analogue activity and restored intratesticular testosterone.

Step 3: Consider clomiphene as a bridge or alternative. Clomiphene citrate 25 to 50 mg daily blocks estrogen receptors at the hypothalamus, removing negative feedback and driving endogenous LH and FSH release. This is an off-label but widely used approach. It also manages hypogonadal symptoms for some patients, making it a reasonable alternative to injectable testosterone for men who want partial symptom relief without gonadotropin suppression. Serum testosterone on clomiphene typically reaches 400 to 600 ng/dL, which is lower than most TRT targets but sufficient for symptom control in many patients.

Step 4: Monitor with serial semen analyses. Repeat semen analysis at 3 months, 6 months, and 12 months post-discontinuation. The first sample showing any sperm does not mean recovery is complete. Total motile count and progressive motility trends over time are more informative than a single data point. If azoospermia persists at 12 months despite gonadotropin therapy, referral to a reproductive urologist for testicular sperm extraction evaluation is appropriate.

When Stopping May Not Fully Reverse the Damage

This is the conversation most TRT prescribers avoid, and patients deserve to hear it plainly. Recovery of spermatogenesis after testosterone cypionate is probable but not guaranteed. Factors that raise the risk of incomplete recovery include: duration of TRT beyond 24 months, pre-existing borderline spermatogenesis before starting, advanced age (over 45), and any concurrent use of anabolic steroids at supraphysiologic doses. A small but meaningful proportion of men remain azoospermic or severely oligospermic at 12 months despite appropriate gonadotropin therapy. For these patients, options include testicular sperm extraction for IVF/ICSI, donor sperm, or accepting permanent infertility as an outcome. Sperm banking before starting testosterone, or before stopping if any motile sperm remain, is the only complete insurance against this outcome.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. World Health Organization Task Force on Methods for the Regulation of Male Fertility. "Contraceptive efficacy of testosterone-induced azoospermia in normal men." Lancet. 1990;336(8721):955-959. https://pubmed.ncbi.nlm.nih.gov/2112639/

  2. World Health Organization. "WHO laboratory manual for the examination and processing of human semen, 6th edition." 2021. https://pubmed.ncbi.nlm.nih.gov/33660308/

  3. Coviello AD, Matsumoto AM, Bremner WJ, et al. "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression." Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2595-2602. https://pubmed.ncbi.nlm.nih.gov/15705929/

  4. Ramasamy R, Scovell JM, Kovac JR, et al. "Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy." Journal of Urology. 2014. https://pubmed.ncbi.nlm.nih.gov/25280080/

  5. Kolettis PN, Purcell ML, Parker W, Poston T, Sandlow JI. "Medical testosterone: an iatrogenic cause of male infertility and a growing problem." Fertility and Sterility. 2016. https://pubmed.ncbi.nlm.nih.gov/27016240/

  6. Lipshultz LI, Khera M, Lipshultz LI. "Hypogonadism and infertility: the overlap." Journal of Andrology. 2010. https://pubmed.ncbi.nlm.nih.gov/20716357/

  7. Bhasin S, Brito JP, Cunningham GR, et al. "Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/